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Abstract
Objective: The purpose of this study was to evaluate the pharmacokinetics of a single dose of selenium (Se)
from yeast given to humans with a habitual long-term daily intake at a supra-nutritional level.
Methods: Twelve healthy males with a daily supplemental intake of 300 mg Se as selenised yeast over 10 weeks
were supplemented with a single dose of 327 mg as stable 77Se incorporated into selenised yeast manufactured
by the same standardised process (SelenoPrecise†, Pharma Nord, Denmark).
Results: Absorption of Se from 77Se-enriched yeast was 8994% and the retention was 7496%. The 77Se
excretion from the single-dose was 47915 mg in urine and 37913 mg in faeces. The maximum, enriched 77Se
concentration in plasma was 9.891.5 mg/l and the time to maximum was 9.2 hours. The plasma halftime of
77Se was longer with increasing time; 1.7 days for the initial phase (½-2 days), 3.0 days for the middle phase
(23 days) and 11.1 days for the later phase (314 days).
Conclusion: The Se from the standardised Se-enriched yeast was well absorbed and retained in the body.
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elenium (Se) intake in many European countries is
relatively low (1) due to the low soil Se concentra-
tions or poor bioavailability of soil Se for uptake
into the plant roots in a great part of Europe. The
recommended daily allowances of Se is 50 mg for men and
40 mg for women in the Nordic countries (2), and is based
on saturation of the activity of glutathione peroxidase -3
(GSH-Px-3) in plasma. However, saturation of GSH-Px-3
occurs at a relatively low intake of Se (40 mg/d) compared
to the intake of Se needed to saturate GSH-Px-1 in
erythrocytes (6080 mg/d) or GSH-Px-1 in platelets (100
110 mg/d). Dietary Se intake may be sub-optimal with
respect to prevention of disease, notably in populations of
adults in the UK, parts of Europe and China, New
Zealand and in the USA (1). There have been indications
that certain forms of cancer might be prevented by intake
of Se as selenised yeast (Se-yeast), in doses that are higher
than required in order to saturate the selenoenzymes (1,
3). Recently, it has been hypothesised that Se intake in the
range of 40100 mg/d primarily has antioxidant and
immune-strengthening effects, while intake in the range
200500 mg/d has specific cancer-preventive properties
(4). An intake of Se of this magnitude is, however,
difficult to obtain from the diet in most parts of the
world where Se content and bioavailability from soils is
moderate or low.
Selenium can be found in a number of different Se-
containing molecules (species), which are absorbed from
the intestinal tract, but retained in different fractions
depending on the species (5). Rat studies have shown that
selenomethionine (Se-meth) is absorbed by an active
transport mechanism, which is shared with methionine,
while other species are absorbed by sharing an active
transport system with other amino-acids, by simple
diffusion or by Na-depending transport systems (6).
Selenium is primarily excreted via urine and faeces. The
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amounts in urine and faeces have been shown to be of
similar magnitude when Se intake is low (7). The most
important factors that influence Se excretion are prob-
ably the amount and form of dietary intake and Se status
of the individual. Whole-body retention studies in young
women following oral administration of radioactive 75Se-
meth have shown that Se elimination is triphasic (8).
Few studies have made use of the stable isotope
technique for measurement of Se absorption, excretion
and retention in humans. To our knowledge, no study has
previously been published on estimation of the absorp-
tion and retention of a single dose of Se-yeast in
individuals with a supra-nutritional Se intake at the 300
mg/day level. The aims of this study were to measure the
absorption, excretion and retention of Se contained in
intrinsically labelled yeast in humans with a high habitual
Se intake. The enriched stable isotope approach using
77Se-SelenoPrecise yeast was applied for the measure-
ments of absorption, retention, and excretion. Further-
more, the pharmacokinetics in a real-life situation of
long-term supplementation with Se was investigated.
Materials and Methods
Study design
The study was a single dose study with 12 healthy
volunteers and was conducted as a pharmacokinetic
study. Nine of the subjects were taking Se-supplements
regularly and in an attempt to standardise Se intake,
subjects were instructed to take 300 mg Se as Se-yeast for
ten weeks before entering the study. The stable 77Se
isotope was taken as intrinsically 77Se-labelled yeast
under standardised, controlled conditions. Eleven blood
samples were taken after administration of the stable
isotope at baseline, after 30 min, 1, 2, 4, 6, 8, 12, 24, 48
and 72 hours. 24 h pooled urines were collected the day
before and 3 days after, and faeces was collected the day
before and for 5 days after 77Se administration. Finally,
blood, 24 h urine and faeces samples were collected after
14 days for six volunteers randomly selected prior to the
beginning of the study.
Subjects
Twelve healthy males volunteered for the study (Table 1).
The average age was 38 years (2651 years), average body
mass index (BMI) was 25.092.3 kg/m2, and mean fat
mass 19.193.2% (Bio-electrical Impedance Analysis,
Omron BF 302, Hoofddorp, Netherlands).
None of the volunteers had any major illness, was
treated with medicine, had allergy to Paraaminobenzoic
acid (PABA), practised sport at an elite level, or had
participated in other clinical studies within a month
before inclusion into the present study. The volunteers
were examined by a physician, prior to inclusion into the
study. Eight of the 12 volunteers were smokers. The
average duration of smoking was 18.398.6 years and the
average number of cigarettes per day was 16.893.7. The
volunteers were assigned to an intake of 300 mg Se as Se-
yeast for 10 weeks before entering the study. Nine of the
volunteers had an even longer history of taking organic
Se as Se-meth or Se-yeast, usually in amounts of
approximately 100 mg/day (mean intake (min-max) were
119 mg/d (62.5225 mg/d). Mean total plasma Se was
182914 mg/l and mean whole blood Se was 213923 mg/l.
The volunteers continued their habitual intake of food
supplements, but were not allowed to take other Se
containing products except the 300 mg Se/day as Se-yeast.
Table 1 shows the mean baseline whole blood Se and also
baseline values of other selected biomarkers, which are all
within normal range for a healthy population.
The study was approved by the local ethical committee
(Fyn and Vejle County, Denmark, Ref. no 2000-0143)
and was conducted in accordance with the Declaration of
Helsinki (including amendments of Tokyo 1975, Venice
1983, Hong Kong 1989 and Sommerset West 1996). All
participants signed an informed consent form.
Test meal
The stable isotope-labelled yeast was given together with
a light meal after an overnight fast. The test meal
consisted of one serving of mu¨sli with 200 ml milk
(1.5% fat), two slices toast with 10 gram of butter,
marmalade, two slices of cheese and one cup of tea or
coffee. Nutrient values were calculated using the Dankost
2000† dietary assessment software (Danish Catering
Center, Herlev, Denmark) (9). The total energy in the
meal was 2.9 MJ. Protein content was 16.1%, lipid
content was 29.3% and carbohydrate content was 54.6%
of the total energy. The calculated content of Se in the
meal was 8.4 mg.
Preparation of selenium supplement
The 10 weeks unlabelled run-in Se preparation used
(SelenoPrecise†, Pharma Nord, Denmark) was produced
Table 1. Characteristics of the 12 human male volunteers at baseline
Mean SD
Age (years) 37.7 8.4
BMI (kg/m2) 25 2.3
Body fat (%) 19.1 3.2
Hb (g/dl) 15.7 0.8
Ht (%) 49.8 2.5
B-Se (mg/L) 212 23
Hg (mg/L) 1.6 0.9
BMIbody mass index, Hbhaemoglobin, Hthaematocrit, B-Se
whole blood Se, Hgmercury.
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by a standardised procedure using a Pharmacopoeia-
controlled growth medium, as a source of carbon,
nitrogen, micronutrients, and yeast of Saccharomyces
cerevisiae (strain PN0056). The yeast was grown aero-
bically under controlled addition of sodium selenite
(Na2SeO3) with a natural Se isotope distribution (abun-
dance of 77Se7.63%). The yeast metabolised more than
95% of the added Se, which was incorporated into a
range of organic Se-species. The predominant species was
Se-meth (81% of all separated and quantified Se species
in the enzymatic hydrolysate or corresponding to 60% of
the total Se content in the yeast), and the residual selenite
(SeO3
2) in the yeast was less than 1% as determined by
enzymolysis and HPLC-ICP-MS (10). The yeast was
harvested, washed, pasteurised, spray dried and pro-
cessed to tablets. The potency of 300 mg per tablet was
confirmed by analyses to lie within±5% of the target
value. The Se yeast, its speciation and long-term bioavail-
ability at dose-levels of 100, 200 and 300 mg/day has been
described in further detail by Larsen et al (11).
The intrinsically labelled single dose of 77Se-
SelenoPrecise† (Pharma Nord, Denmark) contained
329.0 mg total Se, which included 327±9 mg of 77Se
(Chemgas, Boulogne, France) and was produced by the
same procedure as indicated above, except that the
isotopically enriched Na2SeO3 used as substrate con-
tained 77Se at 99.3%. Furthermore, the yeast was freeze-
dried instead of spray-dried. The isotopic composition
and concentration of Se in the 77Se-enriched yeast was
characterised by mass spectrometric analyses to allow for
an accurate administration of the isotope. Speciation
analyses showed that Se-meth amounted to 82% of all
separated and quantified Se species in the enzymatic
hydrolysate, or to 53% of the total Se content in the yeast.
The content of SeO32
 was less than 1% (10). The 77Se-
SelenoPrecise yeast was filled into hard gelatine capsules
by single weighing of the individual capsules to achieve
327 mg 77Se per dose.
Sample collection and preparation
Total faecal samples were collected from the 12 volun-
teers in acid washed plastic containers for one day before
administration of the 77Se-yeast and for 5 days thereafter,
and again for one day after 14 days for 6 of the 12
volunteers. To control the origin in time of the collected
faeces samples (12), four different radio-opaque faecal
markers (Medi-Fakt, Go¨teborg, Sweden) were consumed
in hard gelatine capsules (320 markers per day taken at
breakfast, lunch and dinner), one day prior to and during
the faecal collection. A total of 60 markers represented
one day. One shape of faecal markers were given on the
two days prior to the test meal, another shape of faecal
markers were given together with the test meal and a third
shape of markers were given to the other two main meals
on the test day. A fourth shape of markers was given the
following days. This made possible to distinguish between
faeces from the day before, from the time of intake, from
the first day and the 5 days following administration of
the isotope. The faeces samples were pooled accordingly.
24-h urine was collected the day before and 3 days after
77Se administration and again after 14 days for six of the
volunteers. To control complete collection of urine PABA
tablets (380 mg) were consumed at the same days as the
urine collection (13).
Blood for plasma analyses was drawn at ½ (base-
line), ½, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours and for half of
the group additionally after 14 days after intake of the
stable isotope yeast preparation. Blood was drawn into
heparin tubes (Becton-Dickinson, NJ, USA). The blood
was centrifuged at room temperature for 10 minutes at
3000 rpm, plasma was pipetted into plastic vials and kept
at 208C until the time of analysis of plasma Se. At
baseline (½ h) blood was also drawn into a heparin
tube and kept at 208C until analysis of trace elements
and creatinine.
Analytical methods
Faeces samples were freeze-dried, homogenised, micro-
wave digested using nitric acid (14) and then pooled
according to the content of faecal markers (15). Prior to
Se analysis, the plasma and urine samples and the
digested faeces samples were diluted using an aqueous
diluent containing 0.5% Triton X-100, 2% nitric acid and
3% methanol. An ELAN 6100 ICP-MS instrument
(Perkin-Elmer SCIEX, Concord, Ont., Canada), which
was equipped with a dynamic reaction cell (DRC), was
used for the interference-free Se measurements as the
DRC removed the argon dimer interferences (16). Sele-
nium was detected in all samples as 76Se, 77Se and as 80Se
and quantified by the method of standard additions
(17).The degree of enrichment in 77Se, was estimated
from the total amount of 77Se (supplemented plus
endogenous) minus the endogenous amount of 77Se.
The total amount of endogenous Se with a natural
isotopic composition was quantified from measurement
of 80Se, the abundance of which was not altered by the
administered single dose of 99.3% pure 77Se isotope. The
total Se content in the samples was calculated as the sum
of the 77Se-enriched and endogenous concentrations of
Se. The minimum detectable increase in 77Se was 0.38 mg/
l, 0.58 mg/l and 15 mg/kg for plasma, urine and faeces,
respectively. The reproducibility was estimated by ran-
dom duplicate analyses and the accuracy by analysis of
the reference materials Seronorm Serum (Nycomed
Pharma Dianostics, Oslo, Norway) and BCR CRM 185
Bovine Liver (BCR, Institute for Reference Materials and
Measurements, Geel, Belgium) in parallel with samples
(17). Urine was also analysed for PABA (13) and
Pharmacokinetics of selenium from yeast
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creatinine (Jaffe´ Method, Roche Diagnostics GmbH,
Mannheim, Germany) was measured in urine and
plasma.
Statistics and calculation
The enriched concentrations of 77Se in the individual
samples of plasma, urine and faeces were integrated to
yield the amount of the isotope that appeared in these
biological samples from each human volunteer (17). Only
faecal samples, which contained radio-opaque markers,
originated from the meal with the 77Se-yeast administra-
tion, or with markers taken later than this, were included.
77Se mass balances were established and based on all days
of faecal and urinary collections. The total 77Se content
of the faecal and urinary samples was analysed and
excretion of faecal radio-opaque markers was used to
calculate average daily excretion. The apparent absorp-
tion of 77Se was calculated as the difference between the
intake of 77Se tracer and the amount of tracer from this
intake found in faeces during the collection period. The
retention of 77Se was calculated from the difference
between the administered amount of 77Se and the sum
of faecal and urinary excretions during the collection
period.
One-way ANOVA was conducted for the data at
different time-points. The significance level was prede-
fined as 95%. Correlation between creatinine clearance
and total urine 77Se was examined in a scatterplot.
Results
Compliance
Compliance was assessed directly by supervising the
intake of the 77Se-preparation. On the day of isotope
administration the diet was standardised. The rest of
the time participants were asked about compliance with
the protocol when returning specimens. Compliance for
the 77Se preparation was 100%. Compliance for the 10
weeks daily intake of 300 mg Se as SelenoPrecise yeast
before the study start was 90% or better, which was
controlled by interviewing each participant. One of the
participants reported that he forgot to take one capsule of
the radio-opaque faecal markers (day five in the collec-
tion period), the rest of the participants had 100%
compliance. One of the participants missed one blood
drawing because of illness (diarrhoea and vomiting at day
4). The completeness of urine collection was controlled
by analysis of PABA, which showed a full recovery of
(mean and SD) 108%96.6%. Radio-opaque faecal mar-
kers controlled the complete collection of faeces originat-
ing from the day of 77Se administration. The 77Se
preparation was taken at the same time as the 20
identifiable radio-opaque faecal markers. Retrieval of at
least 18 of 20 markers was considered as a full sample
collection. All the participants were found to have
complete faeces collection. As an extra control of the
urine and faeces collection the participants were asked
every day for any irregularities in their collection. Three
subjects did not collect faeces on day 4 and 5 due to either
irregular defecation or constipation. Other reported
irregularities were negligible.
Selenium pharmaco-dynamics
The apparent absorption of Se from a single dose of 327
mg 77Se as Se yeast was found to be 88.793.9% in
the Danish men with a high habitual Se intake (Table 2).
The mean 77Se excretion from the single dose over the
collection days in urine and faeces was 47.4914.8 mg and
37.1912.7 mg, respectively. The 77Se excretion in urine is
shown in Fig. 1. The 77Se tracer percentage in faeces over
the period is shown in Fig. 2. The mean 77Se retention at
day 4 was 242919 mg/d, which corresponds to 74.29
5.9% of the 77Se intake. The results for the mean 77Se
plasma concentrations during the 72 h following admin-
istration of 77Se are shown in Fig. 3. The mean 77Se
plasma concentration at day 14 was 2.2890.18 mg/l (n
6) (not shown). The maximum 77Se concentration in
plasma was reached after six hours (n1), eight hours
Table 2. Intake, absorption, excretion and retention of 327 mg 77Se administered as a single dose to 12 men with a habitual high intake of Se. The
values are based on urinary and faecal excretion from days 13 after administration of 77Se. Values are given as median values with 1090% per-
centiles and also as means9standard deviation. Values are further given as % of the ingested dose with 1090% percentiles and also9standard
deviation.
mg %
Median (1090 pct) Mean (SD) Median (1090 pct) Mean (SD)
Intake  327  100
Absorption 284 (281308) 290 (13) 87 (8694) 89 (4)
Retention 248 (220258) 242 (19) 76 (6779) 74 (6)
Faecal excretion 43 (1946) 37 (13) 13 (614) 11 (4)
Urinary excretion 44 (3661) 47 (15) 14 (1119) 15 (5)
S Bu¨gel et al
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(n7), and 12 hours (n4). The mean Tmax was 9.17
hours (median Tmax8 h) and the mean
77Se plasma
Cmax from the single dose was 9.7891.53 mg/l. The half-
time of 77Se in plasma (n6) was longer with increasing
time; 1.7 days for the initial phase (½-2 days), 3.0 days for
the middle phase (23 days) and 11.1 days for the later
phase (314 days). The mean plasma Se concentration
(not shown) varied slightly, but statistically non-signifi-
cant, between days 014.
Creatinine clearance was calculated based on serum
creatinine, 24 h urine creatinine excretion and on diuresis
within 24 h. The urinary creatinine clearance was within
the normal range for the age group (0.8  2.8 ml/s). No
relation was found between creatinine clearance and total
urine 77Se excretion (data not shown).
Side effects
One subject reported pharyngitis for three days, one had
hay fever for one day, and one had diarrhoea and
vomiting for one day. None of these reactions were
associated with the yeast-based Se supplements. No other
adverse effects were observed. Two of the subjects took
medication during the study. One received treatment with
penicillin due to pharyngitis in the beginning of the
collection period, and one had a short attack of hay fever
and took anti-histamine.
Discussion
Intake of Se in the range of 200500 mg/d has been
suggested to be anticarcinogenic (3). However, intakes of
this magnitude are difficult to obtain from the diet and
therefore there might be a need for safe and efficient
supplements. A number of studies have compared the
metabolic fate of inorganic Se (selenite and selenate) or
SeMeth given in foods or as supplement (18, 19). These
previous studies have shown that besides the chemical
form of ingested Se and Se status of the individual, other
factors e.g. age, alcohol consumption, smoking and
hormonal therapy might also affect Se metabolism and
status (20, 21).
The high absorption of Se observed in the present
study in participants with a high habitual Se intake is in
agreement with previous studies (7, 18, 22). The absorbed
fraction of Se from different Se yeasts is known to be
large, but the absorption and bioavailability of Se vary
between different batches of Se-yeast (23), which makes
comparisons of results from studies using different Se-
yeast difficult. A comparative study showed, that the
human absorption of Se from different Se-yeasts, as
expressed by plasma Se concentrations, depended on
baseline Se status or on Se speciation in the yeast-based
preparations used (24). Other research groups have also
shown that the whole-body Se content is a critical factor
affecting the homeostatic metabolism of newly ingested
Se (18, 19, 25, 26), and the reason is probably that some
adaptation to different intakes occur. Some studies have
shown that the fractional absorption actually increases by
increasing the intake of Se (19, 25) and although this
study was not designed to compare absorption at high
and low intakes of Se, this would suggest that absorption
is not a major regulator of homeostasis of Se.
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Fig. 1. Mean tracer in urine from the single 77Se dose
detectable before administration (day 0) of a single oral dose
and at day 1, 2, 3, and 14 after tracer administration
(Mean9SD; Day 0 to 3: n12; Day 14: n6).
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Fig. 2. Mean tracer in faeces from the single 77Se dose as
percentage of the total selenium detectable before marker
excretion (day 0) and in samples of day 1  3, 4  5, and day
14 after tracer excretion. The periods were pooled according
to the markers taken simultaneous with the single dose. The
data are presented as mean values9SD with 12 specimens at
day 0 and day 13. The data of day 45 and day 14 included
9 and 6 specimens, respectively.
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Fig. 3. Mean plasma 77Se tracer concentration (mg/L) in 12
human volunteers given a single oral dose of 327 mg 77Se as
Selenium yeast together with a light meal after an overnight
fast (Mean9SD; n12).
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Regarding the Se speciation of the SelenoPrecise yeast,
analysis by HPLC-ICPMS following enzymatic hydro-
lysis showed, that SeMeth constituted 60% of the total Se
content in the yeast (10). Selenocysteine was not detected
in the yeast, which was in accordance with the fact that
the yeast genome does not include the necessary codon
for its biosynthesis (27). The remainder of the Se was
present as more than 30 unknown Se-species of low
abundance whereas selenite and SeMeth Se-oxide were
present at less than 1% of the total Se content in the
yeast. The identity of Se species, which correspond to the
non-extractable fraction (26%), remained unknown (10).
A separate study characterised the Se species contained in
the 77Se-SelenoPrecise yeast used in this study (10). The
results showed that approximately 55% of the total Se in
the yeast was present as SeMeth, which was similar to the
value found for the SelenoPrecise yeast.
Selenium excretion occurs primarily via urine and
faeces (8). Levels of faecal excretion of Se have been
reported to be similar to levels of urinary Se excretion
when dietary levels of Se are not excessive. In the present
study we observed a relatively low excretion of Se from
urine (15%) and faeces (11%) of a single 77Se dose during
the first 4 days. The majority of the urinary Se was
excreted within the first 24 hours after intake of 77Se and
thereafter excretion was reduced to low levels. The same
tendency was observed for the faecal excretion, although
the 77Se faecal excretion remained high until 4872 hours
after the single 77Se supplementation (results not shown).
This might indicate entero-hepatic recirculation in agree-
ment with previous studies with SeMeth (28) showing
that a significant proportion (46%) of the amount leaving
the liver was found to re-enter the intestines.
The analytical results of plasma and urine samples
from day 1 to day 14 showed that the elimination of 77Se
was not complete and that the plasma concentration was
approximately 20% of the initial peak plasma concentra-
tion. At day 14 the 77Se excretion was still on-going, as
the 77Se concentration in urine and faeces had not
returned to baseline. The total amount of 77Se excreted
at day 14 was 1.61 mg, 48% of which was excreted via
kidneys to urine and 52% was excreted via faeces.
A kinetic model for SeMeth was proposed by Patterson
et al (29) who suggested that SeMeth is extensively
recirculated and passed through liver, pancreas and
peripheral tissues many times before being excreted.
This would explain that labelled Se is still found in faeces
and urine 2 weeks after administration. The same was
observed a year after labelling of body pools by Veillon et
al (30). In the present study we also observed a high
excretion of total Se in both urine and faeces (data not
shown), which reflects the high intake of Se in this group
of people and is in accordance with results from other
studies feeding high amounts of Se (19). We cannot,
however, from our data, conclude if this is caused by
adaptation to the higher intake. In the study by Hawkes
(19) it was observed that when the intake of Se was
increased from normal (47 mg/d) to high (297 mg/d), the
urinary and faecal excretion of Se almost doubled, while
deposition in muscles increased by approximately 25%
during the 99 days with high Se intake. It is likely that the
high intake in our study has changed the distribution of
Se in the body.
According to Clark et al. (3) steady state in plasma-Se
with a supplemented daily dose of 200 mg Se as Se yeast
was reached after 69 months, and Clark et al. observed a
plateau of approximately 190 mg/l after one year and for
the next 9 years of his observational period. When 300 mg
Se per day of the same standardised yeast (SelenoPrecise)
was given to a UK cohort (n 103) for 6 months the
mean plasma-Se was raised from 92920 mg/l to 233954
mg/l (11). In the present study, the plasma Se concentra-
tion was 182914 mg/l after 10 weeks supplementation
with 300 mg Se/d. When 0, 100, 200 or 300 mg/day of the
same standardised yeast was given to a Danish cohort
(n49) for two years, the Se-whole-blood response was
linearly proportional to the total daily intake. The mean
blood-Se level in the 300 mg intake group, which was
4419132 mg/l, was in steady state after 2 years supple-
mentation (11). The blood-Se concentration was 213923
mg/l, in the present study, after 10 weeks administration
of an identical Se-yeast. The 10 weeks pre-supplementa-
tion in the present study with 300 mg Se/day is therefore
not sufficiently long to fully attain steady state. This is
likely to have affected the validity of the results.
In the present study, the mean 77Se plasma maximum
concentration was 9.7791.53 mg/l where the median Tmax
was 8 hours and the mean Tmax was found at 9.17 hours.
The Tmax results observed in our study were in agreement
with a previously reported Tmax at approximately 8 hours
after supplementation of 100 mg 74selenate (18). Finley
(18) found a plasma maximum concentration of approxi-
mately 5.3 mg/l, which was considerably lower than the
plasma maximum observed in the present study, but this
is probably a reflection of the chemical form of Se given,
as well as the dose. Higher plasma concentrations have
been observed in studies feeding SeMeth, compared to
other chemical forms of Se (31, 32).
The mean plasma Se concentration observed in this
study was considerably higher than values reported in un-
supplemented Danish subjects; 7595 mg/l (14, 33), but
was closer to results reported in other studies, which
reported plasma concentrations from 111190 mg/l in
humans supplemented with 100200 mg Se yeast (3, 34).
This confirms that the subjects did take the supplements.
A number of factors might have affected the results
obtained in this study, among these are the fact that
although our subjects’ year-long high Se intakes, the Se
species and amounts of intakes differed among the
subjects and the 10 week run-in period obviously was
S Bu¨gel et al
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not sufficient to obtain steady-state. Furthermore, 8 of
our subjects were current smokers and this as well might
have affected the results as some studies have indicated
that smoking might affect Se status (20). We think,
however, that for the purpose of this study these factors
have only minor effects.
Conclusion
In conclusion, the absorption and three days retention in
Danish men with a high habitual Se intake was found to
be high as investigated by the stable enriched isotope
approach using a single dose of 77Se-labelled SelenoPre-
cise yeast.
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